A unique opportunity for exchanges:

  • Showcasing the excellence and expertise of French academic research teams
  • Discussing innovative projects
  • Establishing partnerships, promoting international investments, and supporting France’s competitiveness globally


  • Morning: Presentation of cutting-edge results by industrial and academic researchers (roundtable discussions, academic pitches, presentation of public-private partnerships).
  • Afternoon: Individual meetings between researchers from the academic or industrial world.

Public-private partnerships (PPPs) are essential for fostering innovation in the healthcare industries. Whether organized upstream in fundamental research or downstream for treatment development, or both, and whether they are part of established structures set up for this purpose, partnerships can take various forms depending on the projects and targeted needs.

Thanks to a wide range of opportunities, it is now easier for researchers, both academic and industrial, to develop lasting relationships. Many options are available to them: simple collaborative R&D contracts, open strategic partnerships for innovation, research consortia funded by the European Commission, and more.

France is an excellent hub that plays a key role in the overall R&D strategy of healthcare companies. Its healthcare networks, clinical research, and ethical standards are exceptional. Its institutions and universities, along with the excellence of its fundamental research and scientists, are fully capable of meeting the challenges of international competition.

The establishment of the Strategic Council for Healthcare Industries, followed by the creation of AVIESAN and ariis, are three major advances that have significantly accelerated the rapprochement between the public and private sectors. Established in 2004, the Strategic Council for Healthcare Industries (CSIS) is a forum for informal and open debates and exchanges, allowing public authorities to better understand the constraints, challenges, and ambitions of the sector, and for industrial players to better perceive the requirements of different public policies in order to adjust their business strategies. It is within the framework of the CSIS that the industry and public actors can set common objectives. The sustainability of the French International Research and Development Network (RIR) was one of the recommendations of the 5th CSIS meeting in 2012.

The creation of the National Alliance for Life Sciences and Health (AVIESAN), which promotes closer collaboration between major national research organizations, university hospitals, and universities, has profoundly changed the conditions for the development of partnership research. By fostering new dynamics, creating appropriate structures, and limiting the number of potential public interlocutors, AVIESAN has facilitated the development of industrial research programs in association with public institutions.

The success of this measure was reinforced by the parallel creation in 2010 of the French Alliance for Research and Innovation in Healthcare Industries (ariis), which plays the same coordinating role between different industrial actors and has become the natural institutional contact point for AVIESAN. Since its creation, ariis has aimed to develop public/private and private/private partnerships to promote synergies between pharmaceuticals, medical devices, diagnostics, biotechnologies, and to establish the best environment to foster innovation in healthcare. Unique in the world, ariis is an essential asset for France’s competitiveness and attractiveness, as it promotes the development of innovative products, from idea to patient availability, by bringing together all actors in the healthcare industry.

Regarding PPPs, the annual international R&D meetings co-organized by ariis and AVIESAN are probably a unique initiative that has generated over the past 7 years more than 700 meetings between academic and industrial researchers in the fields of cancer, cardiovascular and metabolic diseases, infectious diseases, neuroscience, inflammation, rare diseases, and personalized medicine.


Last editions

2018 - Immuno-oncology

Considered by the American Society of Clinical Oncology (ASCO) as the “Clinical Advance of the Year 2017”, immuno-oncology is now part of the therapeutic arsenal used against advanced cancers or recurrences. Initially used for prostate and melanoma, these treatments are increasingly effective against other cancers: Hodgkin’s lymphoma, kidney, lung, and even certain hematological cancers.

Find the program here and the 2018 press release  here.

2016 - Neurosciences and psychiatry

Place : Salons de l’Aveyron, Paris

Degenerative neurological diseases (Alzheimer’s, Parkinson’s, dementia, multiple sclerosis), disorders related to innate or acquired neural dysfunctions (epilepsy, strokes), and psychiatric disorders (anxiety, depression, addiction, schizophrenia, autism, obsessive-compulsive disorders) share certain biological alteration signatures, forming several priority avenues for innovative therapies.

Find the program here, the press release here and the 2016 overview here.

2015 - Rare diseases and personalized medicine

Place : Collège de France, Paris

Rare diseases, defined by a frequency of less than 1/2000, are predominantly genetic diseases. They represent a paradigm for the development of personalized medicine, aiming to ensure early diagnosis, prevention, and treatment of diseases based on individual characteristics. Rare diseases often correspond to extreme forms of common diseases. Therefore, deciphering the molecular and biological mechanisms of rare diseases from gene identification has broader relevance for many common diseases.

Find the program here and the 2015 press release here.

2013 - The inflammatory diseases

Place: Carrousel du Louvre, Paris

Inflammation is a global public health priority. In France, more than 80 research teams are working on inflammation and/or inflammatory diseases. These teams have made significant advances in the molecular and cellular basis of inflammation, as well as in clinical research, epidemiology, public health, and translational research. The collective results obtained contribute to a better understanding of inflammatory diseases.

Find the program here and the 2013 press release here.

2012 - Cancer: Research and Innovations

Place: La Maison de la Chimie, Paris

A priority for researchers and the healthcare industry, cancer research has led to significant advancements over the past 20 years. France has developed and implemented numerous tools to facilitate the transfer of research into innovation, including molecular genetics platforms enabling access to tailored and more efficient treatments, early clinical trial centers, and integrated cancer research sites.

Find the program here, the press release here and the 2012 press kit here.

2011 - Infectious diseases

Place : L’Hôtel de Marigny, Paris

The 2011 theme “Infectious Diseases” brought together, under the leadership of Professor Jean-François Delfraissy, director of the ITMO “Microbiology and Infectious Diseases” and general director of the National Agency for Research on AIDS and viral hepatitis (ANRS), nearly fifty researchers from AVIESAN and an equal number of R&D directors from human and veterinary pharmaceutical companies and diagnostic companies worldwide. This international participation reflects the importance attached by the scientific community to these minutely scheduled meetings, inspired by Anglo-Saxon methods of “business dating.”

Find the program here, the press release here, the report and the 2011 assessment.